May 15, 2025

Periodontitis Emerges as Modifiable Risk Factor for AMD

Inflammatory mediators are shared between the conditions.

Conexiant

May 15, 2025

Visual Difficulty, Falls, and Mortality

Recurrent falls were associated with a nearly 50% increased hazard of mortality.

Conexiant

May 08, 2025

Alkeus Presents Data at ARVO on Oral Gildeuretinol for GA

Data were presented from Alkeus Pharmaceuticals’ phase 2 SAGA clinical study in GA secondary to AMD.

Ophthalmology Management

May 05, 2025

PDS Updates Continue to Reduce Treatment Burden for Patients with nAMD, DME, and DR

These types of improvements are relatively common after initial approval and are the result of optimization as surgical techniques and knowledge evolve.

Conexiant

September 18, 2024

Assessing the Impact of iRORA Lesions on Retina Sensitivity and Function

A new case study explores the impact of incomplete retinal pigment epithelium and outer retinal atrophy lesions on retinal sensitivity in intermediate age-related macular degeneration, shedding light on potential surrogate markers for retinal dysfunction. (Source: BMJ Open Ophthalmology)

Conexiant

April 09, 2025

Port Delivery System With Ranibizumab for Diabetic Eye Disease

Researchers determined that the PDS may decrease the treatment burden of frequent intravitreal injections, but further research on efficacy and safety is needed.

Conexiant

January 16, 2025

LA County Fires Prompt Business Recovery Centers to Open

"Business owners can meet face-to-face with specialists to apply for disaster loans and access a wide range of resources to guide them through their recovery."

Optometric Management

January 22, 2025

High, Low HDLs Tied to AMD Risk

The lack of association between LDLs and triglycerides and AMD risk “suggests that plasma HDL specifically may play a role in progression to early and intermediate AMD.”

Conexiant

September 30, 2024

Can L-DOPA Protect Against nAMD?

Patients consistently treated with L-DOPA also had lower progression rates from intermediate AMD to nAMD compared to non-treated groups.

Conexiant